Literature DB >> 30055758

Frequency of Statin Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dl from the Veterans Affairs Health System.

Fatima Rodriguez1, Joshua W Knowles2, David J Maron2, Salim S Virani3, Paul A Heidenreich4.   

Abstract

Patients with low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dl have severe hypercholesterolemia and are at markedly increased risk for adverse cardiovascular events. This study sought to examine the prevalence and treatment of patients with uncontrolled severe hypercholesterolemia in the Veterans Affairs (VA) Health System. The study population was comprised of VA outpatients ≥21 years of age without atherosclerotic disease or diabetes mellitus and an index LDL-C ≥190 mg/dl during April 2011 to March 2014. Patients needed to have filled medications at the VA within the past 6 months. Patient and facility-level predictors of statin use, high-intensity statin use, and statin intensification were analyzed using multivariate logistic regressions. There were a total of 63,576 patients meeting inclusion criteria, including 8,553 (13.5%) women and 26,879 (29.0%) nonwhite patients. The mean (±S.D.) age was 55 (±13) years and the mean of the most recent LDL-C values was 207 ± 22 mg/dl. Only 52% of all eligible patients were on any statin therapy and 9.7% received high-intensity statin therapy. High-intensity statin use increased from 8.6% in 2011 to 13.6% in 2014 (p < 0.001). In adjusted analysis, patients <35 or >75 years of age were less likely to be on a statin (p < 0.001). Women were less likely to be treated than men, odds ratio = 0.88; 95% confidence interval (0.83, 0.92). Similar patterns were observed for predictors of high-intensity statin use and statin intensification. In conclusion, only half of high-risk VA patients with uncontrolled severe hypercholesterolemia were treated with statins and a small minority was on high-intensity statin therapy.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30055758      PMCID: PMC6538561          DOI: 10.1016/j.amjcard.2018.05.008

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

Review 1.  The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association.

Authors:  Samuel S Gidding; Mary Ann Champagne; Sarah D de Ferranti; Joep Defesche; Matthew K Ito; Joshua W Knowles; Brian McCrindle; Frederick Raal; Daniel Rader; Raul D Santos; Maria Lopes-Virella; Gerald F Watts; Anthony S Wierzbicki
Journal:  Circulation       Date:  2015-10-28       Impact factor: 29.690

2.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

3.  Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype.

Authors:  Amanda M Perak; Hongyan Ning; Sarah D de Ferranti; Holly C Gooding; John T Wilkins; Donald M Lloyd-Jones
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

4.  Clinical Features and Gaps in the Management of Probable Familial Hypercholesterolemia and Cardiovascular Disease.

Authors:  Barak Zafrir; Ayman Jubran; Gil Lavie; David A Halon; Moshe Y Flugelman; Chen Shapira
Journal:  Circ J       Date:  2017-07-12       Impact factor: 2.993

Review 5.  The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies.

Authors:  Allan D Sniderman; Sotirios Tsimikas; Sergio Fazio
Journal:  J Am Coll Cardiol       Date:  2014-03-12       Impact factor: 24.094

6.  Provider understanding of the 2013 ACC/AHA cholesterol guideline.

Authors:  Salim S Virani; Yashashwi Pokharel; Lynne Steinberg; Winston Chan; Julia M Akeroyd; Saqib Ali Gowani; Ankur Kalra; Venkateshwar Polsani; Michael D Miedema; Peter H Jones; Vijay Nambi; Laura A Petersen; Christie M Ballantyne
Journal:  J Clin Lipidol       Date:  2015-11-17       Impact factor: 4.766

7.  Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Authors:  Paul N Hopkins; Peter P Toth; Christie M Ballantyne; Daniel J Rader
Journal:  J Clin Lipidol       Date:  2011-04-03       Impact factor: 4.766

8.  Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox.

Authors:  Dennis T Ko; Muhammad Mamdani; David A Alter
Journal:  JAMA       Date:  2004-04-21       Impact factor: 56.272

9.  Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia.

Authors:  Amit V Khera; Hong-Hee Won; Gina M Peloso; Kim S Lawson; Traci M Bartz; Xuan Deng; Elisabeth M van Leeuwen; Pradeep Natarajan; Connor A Emdin; Alexander G Bick; Alanna C Morrison; Jennifer A Brody; Namrata Gupta; Akihiro Nomura; Thorsten Kessler; Stefano Duga; Joshua C Bis; Cornelia M van Duijn; L Adrienne Cupples; Bruce Psaty; Daniel J Rader; John Danesh; Heribert Schunkert; Ruth McPherson; Martin Farrall; Hugh Watkins; Eric Lander; James G Wilson; Adolfo Correa; Eric Boerwinkle; Piera Angelica Merlini; Diego Ardissino; Danish Saleheen; Stacey Gabriel; Sekar Kathiresan
Journal:  J Am Coll Cardiol       Date:  2016-04-03       Impact factor: 24.094

10.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

Authors:  Børge G Nordestgaard; M John Chapman; Steve E Humphries; Henry N Ginsberg; Luis Masana; Olivier S Descamps; Olov Wiklund; Robert A Hegele; Frederick J Raal; Joep C Defesche; Albert Wiegman; Raul D Santos; Gerald F Watts; Klaus G Parhofer; G Kees Hovingh; Petri T Kovanen; Catherine Boileau; Maurizio Averna; Jan Borén; Eric Bruckert; Alberico L Catapano; Jan Albert Kuivenhoven; Päivi Pajukanta; Kausik Ray; Anton F H Stalenhoef; Erik Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen
Journal:  Eur Heart J       Date:  2013-08-15       Impact factor: 29.983

View more
  8 in total

1.  Statin Use in Older Adults with Stable Atherosclerotic Cardiovascular Disease.

Authors:  Gabriela Spencer-Bonilla; Sukyung Chung; Ashish Sarraju; Paul Heidenreich; Latha Palaniappan; Fatima Rodriguez
Journal:  J Am Geriatr Soc       Date:  2021-01-07       Impact factor: 5.562

2.  Statin Use in Older Adults for Primary Cardiovascular Disease Prevention Across a Spectrum of Cardiovascular Risk.

Authors:  Ashish Sarraju; Gabriela Spencer-Bonilla; Sukyung Chung; Sofia Gomez; Jiang Li; Paul Heidenreich; Latha Palaniappan; Fatima Rodriguez
Journal:  J Gen Intern Med       Date:  2021-09-10       Impact factor: 6.473

3.  Cardiology clinic visit increases likelihood of evidence-based cholesterol prescribing in severe hypercholesterolemia.

Authors:  Nicole A Groth; Neil J Stone; Catherine P Benziger
Journal:  Clin Cardiol       Date:  2020-12-23       Impact factor: 2.882

4.  Statin Use for Atherosclerotic Cardiovascular Disease Prevention Among Sexual Minority Adults.

Authors:  Yi Guo; Christopher W Wheldon; Hui Shao; Carl J Pepine; Eileen M Handberg; Elizabeth A Shenkman; Jiang Bian
Journal:  J Am Heart Assoc       Date:  2020-12-02       Impact factor: 5.501

5.  Lower-Intensity Statins Contributing to Gaps in Care for Patients With Primary Severe Hypercholesterolemia.

Authors:  Wael E Eid; Emma Hatfield Sapp; Elijah Flerlage; Joseph R Nolan
Journal:  J Am Heart Assoc       Date:  2021-09-01       Impact factor: 5.501

6.  Impact of Race and Location of Residence on Statin Treatment Among Veterans With Type 2 Diabetes Mellitus.

Authors:  Erin R Weeda; Kinfe G Bishu; Ralph C Ward; Elizabeth A Brown; R Neal Axon; David J Taber; Mulugeta Gebregziabher
Journal:  Am J Cardiol       Date:  2020-03-05       Impact factor: 2.778

7.  Use of statins and associated factors in nonagenarians in the Community of Madrid, Spain.

Authors:  Carlos Lahoz; Juan Cárdenas-Valladolid; Miguel Ángel Salinero-Fort; José María Mostaza
Journal:  Aging Clin Exp Res       Date:  2021-08-07       Impact factor: 4.481

8.  Prevalence, treatment, and control of severe hyperlipidemia.

Authors:  Matthew E Gold; Michael G Nanna; Shannon M Doerfler; Tony Schibler; Daniel Wojdyla; Eric D Peterson; Ann Marie Navar
Journal:  Am J Prev Cardiol       Date:  2020-08-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.